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Abstract
 
Contact sensitivity (CS) is a classic example of in vivo T cell immunity in which skin sensiti-
zation with reactive hapten leads to immunized T cells, which are then recruited locally to
mediate antigen-specific inflammation after subsequent skin challenge. We have previously
shown that T cell recruitment in CS is triggered by local activation of complement, which
generates C5a that triggers C5a receptors most likely on mast cells. Here, we show that B-1
cell–derived antihapten IgM antibodies generated within 1 day (d) of immunization combine
with local challenge antigen to activate complement to recruit the T cells. These findings
overturn three widely accepted immune response paradigms by showing that (a) specific IgM
antibodies are required to initiate CS, which is a classical model of T cell immunity thought
exclusively due to T cells, (b) CS priming induces production of specific IgM antibodies
within 1 d, although primary antibody responses typically begin by day 4, and (c) B-1 cells
produce the 1-d IgM response to CS priming, although these cells generally are thought to be
nonresponsive to antigenic stimulation. Coupled with previous evidence, our findings indi-
cate that the elicitation of CS is initiated by rapidly formed IgM antibodies. The IgM and
challenge antigen likely form local complexes that activate complement, generating C5a, lead-
ing to local vascular activation to recruit the antigen-primed effector T cells that mediate the
CS response.
Key words: T cell recruitment • complement C5 and C5a • skin immunity • IgM response • 
T and B cell interactions
 
Introduction
 
Contact sensitivity (CS)
 
*
 
 is a form of delayed-type hyper-
sensitivity (DTH) that is a classic example of in vivo T cell
immunity (1). In mice, CS responsiveness is induced by
primary skin painting immunization on the body with a
concentrated solution of a reactive hapten Ag. Subse-
quently, CS effector immune inflammatory responses are
elicited by challenge, which consists of reexposure via
painting a dilute solution of the same reactive hapten at a
separate skin site, usually the ear. This challenge elicits local
T cell–dependent inflammation that does not occur in sim-
ilarly challenged nonimmune controls. Soon after the elici-
tation of the local secondary response by Ag challenge, very
small numbers (2) of circulating sensitized Ag-specific T
cells, which can be Th1 (1) or Tc1 (3), are recruited into
the extravascular space at the skin challenge site.
A new round of local secondary T cell activation then
occurs via T cell receptor binding to complexes of hapten
conjugated to self- MHC on local APCs, stimulating pro-
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trinitrophenol. 
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duction of effector cytokines like IFN-
 
  
 
(4). The local in-
flammation caused by this T cell recruitment and extravas-
cular activation on APC often peaks at 24 h and is a model
for Th1-mediated inflammation in various diseases such as
autoimmunity, allergies, and immune resistance responses
to some microbes and tumors (1, 3).
The mechanisms involved in CS responses are currently
assumed to operate independently of B cells, antibody, and
complement (1). Under the prevailing paradigm, the initial
sensitizing skin painting with hapten leads to activated epi-
dermal Langerhans APCs with surface-bound complexes of
the hapten self-peptides complexed with MHC. These Ag-
charged APCs then traffic to draining LNs to sensitize re-
circulating specific T cells that can eventually mediate CS
and some DTH effector T cell responses. The effector T
cell responses are elicited after a secondary Ag challenge
that as noted generates hapten–self-MHC complexes on
skin APCs for activating the recruited CS effector T cells.
Thus, according to current thinking, the local presence of
the Ag-charged APCs is sufficient to activate the recruited
sensitized T cells and trigger their production of cytokines,
which are required to generate the full inflammatory phase
of CS that peaks at 24 h (1).
However, our studies demonstrate that this paradigm is
not correct. We have previously shown that the early re-
cruitment of circulating T cells to the site of the extravas-
cular APCs is an essential and regulated mechanism in CS.
In addition, we have shown that this T cell recruitment af-
ter secondary Ag challenge requires early activation of
complement (5–7) and generation of the C5a complement
fragment, which can be detected locally within 1 h (8). Im-
portantly, we showed that this locally generated C5a ini-
tiates a series of events that are required for recruitment of
the T cells that mediate the CS effector response (5, 6, 8).
Discovery of this previously unappreciated and required
local complement activation in CS led to this study. We
now show that B cells and antibody, long excluded in con-
cepts of CS and DTH, are in fact required to activate the
complement that is needed for the early T cell recruitment
needed to elicit the classical late phase of CS responses.
Thus, we implicate B cells and antibodies in assisting T cell
recruitment to mediate the CS effector T cell responses. In
essence, we show that B cells produce specific antibodies
that bind to the challenge Ag and form complement-acti-
vating Ag–antibody complexes required to initiate the elic-
itation of CS, a process we call CS initiation (5, 6, 8).
Our previous studies, which implicated C5/C5a in CS
elicitation, provided an initial indication that B cells are re-
quired for this process (6). However, although we discussed
this idea (9, 10), we did not present definitive evidence on
this point. Thus, we demonstrate here for the first time that
antibodies are clearly involved in initiating the elicitation of
CS by showing that (a) specific IgM antibodies are re-
quired, (b) CS priming uniquely induces the production of
these antibodies within only 1 d, and (c) B-1 cells produce
the CS-initiating 1-d immune IgM antibody response.
In addition, we show that mice lacking B cells, includ-
ing pan B cell–deficient JH
 
 
 
/
 
  
 
and CBA/N-
 
xid
 
 mice,
 
which lack B-1 and some other B cells, do not mount CS
responses, measured either as macroscopic ear swelling or
local 24 h IFN-
 
  
 
elaboration in the ears. Nevertheless, we
also show that priming the B cell–deficient mice generates
CS effector T cells that can respond to secondary Ag chal-
lenge when transferred to an immunized intact host pro-
ducing circulating IgM antibodies against the challenge
Ag. Similarly, we show that the CS effector activity of
these T cells is demonstrable in immunized B cell–defi-
cient mice by injecting these hosts with monoclonal IgM
antibodies specific for the challenge Ag, or by transferring
B-1 cells from donors immunized with the challenge Ag
only 1 d previously. Finally, we complete the demonstra-
tion that IgM antibodies are responsible for early CS initi-
ation that begin the elicitation of CS, whereas T cells me-
diate the later occurring CS effector response. Thus, we
separate the early CS initiation mechanism from the later
CS effector response by showing that different Ag can be
used to induce the initiating IgM antibodies and to prime
the effector T cells mediating the classical late phase of CS
response, as long as both Ag are used together for the sec-
ondary skin challenge.
Coupled with evidence from our previous studies that
focused on C5/C5a, these new findings define the overall
mechanism responsible for CS as follows: (a) B-1 cells
respond within 1 d of CS priming (skin painting) by rap-
idly producing circulating IgM antibodies specific for the
priming Ag, (b) these antibodies initiate the elicitation of
CS responses to secondary challenge (ear painting) by
binding to the challenge Ag and forming local Ag–anti-
body complexes, (c) the complexes activate complement
to generate C5a, which initiates local Th1 cell recruit-
ment, and (d) this enables the elicitation of the classical
late (24-h) CS inflammatory response.
 
Materials and Methods
 
Mice and Reagents.
 
Specific pathogen-free male CBA/J mouse
controls and 6–8-wk-old experimental male CBACa/HN-btk-
 
xid
 
/J (
 
xid
 
) mice deficient in B-1 cells, and female BALB/cJ
(H-2
 
d
 
) (Jackson ImmunoResearch Laboratories) and control
H-2
 
d 
 
CB.17 mice (Taconic Farms) were rested at least 1 wk. B
cell–deficient JH
 
 
 
/
 
  
 
mice (11) were bred and maintained in fil-
tered microisolators in a bio-clean room and fed autoclaved food
and water. Experiments were performed according to guidelines
of the Animal Care and Use Committee at Yale University
School of Medicine. Picryl chloride (PCl; Nacalai Tesque) was
recrystallized twice and oxazolone (4-ethoxymethylene-2-phe-
nyl-2-oxalolin-5-one) (OX) was obtained from Sigma-Aldrich.
Both haptens were stored and protected from light.
 
Immunization and Elicitation of CS.
 
In brief, mice were im-
munized for CS by topical painting on the shaved chest and ab-
domen and the four feet with a total of 150 
 
 
 
l 5% PCl or 3%
OX in 4:1 ethanol/acetone (5, 6, 8). 1 or 4 d later, secondary CS
responses were elicited by topical ear application with 0.4–0.8%
PCl or OX in 1:1 acetone/olive oil, and then observers often
unaware of the groups measured ear thickness with a caliper
(Ozaki) or micrometer (Mitutoyo) before and 2 and 24 h after
challenge. The results from representative experiments using 4–6 
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mice per group are expressed as mean mm 
 
  
 
10
 
 
 
2
 
 
 
  
 
SE com-
pared with age- and sex-matched syngeneic controls shaved and
sham immunized by the application of vehicle alone, and then
identically Ag challenged with measurement of the ears with the
experimental groups.
 
Adoptive Cell Transfer of CS Reactivity.
 
Cell donors were ac-
tively sensitized with 5% PCl or 3% OX. On day 1 or 4, LNs and
spleens were harvested, single cell suspensions prepared, and a
mixture of 5–7 
 
  
 
10
 
7 
 
immune cells, or FACS
 
® 
 
sorted cells in the
numbers indicated, were adoptively transferred intravenously in
0.25 ml PBS into syngeneic recipients. The ear thickness of
groups of 4–6 recipients was measured with a micrometer before
the transfers. 24 h later, the recipients were challenged on each
ear with 10 
 
 
 
l 0.4% PCl or OX in 1:1 olive oil/acetone. The
subsequent increases in ear thickness were determined at 2 and
24 h after challenge and expressed as described above. Nonimmune
mice similarly skin challenged and ear measured at 0, 2, and 24 h
were controls. Their background ear swelling response was 
 
 
 
1
unit 
 
  
 
10
 
 
 
2
 
 mm at 2 h, and 2 units at 24 h. In some experiments,
this control swelling was subtracted from experimental responses
to yield net ear swelling.
 
Purification of Peritoneal B-1 Cells.
 
Peritoneal cells of 36 nor-
mal CBA/J were harvested by lavage with 4 ml cold 1% FBS-
PBS, washed three times, and resuspended in RPMI 1640 con-
taining 10% FBS (GIBCO BRL), 25 mM Hepes, 100 units/ml
penicillin, and 100 
 
 
 
g/ml streptomycin. Macrophages were de-
pleted by plastic adherence for 1 h at 37
 
 
 
C in 5% CO
 
2
 
. These
normal nonimmune peritoneal B-1 cells were FACS
 
® 
 
purified af-
ter staining with biotin-conjugated anti-B220 (CD45RA) mAb
plus FITC-avidin and anti–CD5-PE mAb (BD Biosciences) using
a FACStar™ (Becton Dickinson). Purities of B220
 
  
 
CD5
 
  
 
cells
that were transferred intraperitoneally in 0.5 ml sterile PBS were
 
  
 
98%.
 
FACS
 
® 
 
Sorting of Immune Lymphoid B-1 Cells.
 
Immune spleen
and LN cells (LNCs) at 10
 
6
 
–10
 
7
 
/ml were stained with anti–CD5-
CyChrome and anti–CD19-FITC at 0.025 
 
 
 
g per 10
 
6 
 
cells and
in some experiments also with anti-CD43 PE (BD Biosciences)
for 30 min on ice, and then washed at 4
 
 
 
C with RPMI without
FCS. Stained cells were sorted with a FACSVantage™ SE (Bec-
ton Dickinson) to obtain CD19
 
  
 
CD5
 
  
 
CD43
 
  
 
cells versus
CD19
 
  
 
CD5
 
  
 
CD43
 
  
 
cells, usually at a ratio of 10:1 CD43
 
 
 
/
CD43
 
  
 
cells, or B-1 (CD5
 
 
 
 
 
CD19
 
 
 
) cells versus B-2 (CD5
 
 
 
CD19
 
 
 
) cells (12, 13).
 
In Vitro T Cell Stimulation by Hapten-conjugated APCs.
 
As pre-
viously described (14), normal spleen cells treated with 100 
 
 
 
g/
ml mitomycin C were incubated with 10 mM trinitrobenzene
sulfonic acid to obtain TNP-APCs. 4 
 
  
 
10
 
5 
 
4-d TNP-Cl (PCl)
immune LNCs were incubated in vitro in microwells at 37
 
 
 
C
with varying numbers of TNP-APCs and supernatants were col-
lected at 48 h for subsequent determination of IFN-
 
  
 
content by
ELISA.
 
In Vitro Chemotaxis Assay of CS Ear Extracts.
 
As previously
described (6, 8), when mice were killed ear punch biopsies were
frozen in liquid N
 
2 
 
and then thawed and extracted with a micro-
homogenizer on ice in a microfuge tube after centrifugation. To
remove debris, separate ear extracts from individual mice were
diluted two to four times in RPMI 1640 with RPMI gelatin and
then placed in chemotaxis chambers (Neuroprobe) versus 2–5 
 
 
 
10
 
6 
 
target migrating macrophages of the J774A.1 monocyte/mac-
rophage cell line (American Type Culture Collection), allowing
cell migration through 5–8-
 
 
 
m pore PVP-free polycarbonate fil-
ters. Migrated cells attaching to the lower surface of the filter
were fixed and DiffQuick (Fisher Scientific) stained and five filter
 
spots were counted at 
 
 
 
400 or the filters were extracted with
4 M urea and absorbance of the extracts was measured at 650 nm.
Migration was not due to chemokinesis because ear extracts
added to the cells decreased migration. As previously described
(6, 8), chemotactic activity in ears 2 h after challenge was due al-
most entirely to C5a and at 24 h was due to chemokines, includ-
ing IP-10.
 
Quantitative Sandwich ELISA for IFN-
 
 
 
.
 
As previously de-
scribed (6, 8, 14), wells were coated overnight with capture anti–
IFN-
 
  
 
mAb. After blocking with 1% BSA, the ear extracts or
control recombinant mouse IFN-
 
  
 
(Genzyme) was added for 1 h
at 25
 
 
 
C. After washing, 1 
 
 
 
g/ml of another biotinylated anti–
IFN-
 
  
 
mAb (BD Biosciences) and 1:3,000 horseradish peroxidase
ELISA developing reagents were added.
 
Purification of Anti-TNP IgM.
 
Monoclonal anti-TNP IgM su-
pernatant of 32.17 IgM-producing hybridoma (provided by F.T.
Liu, University of California at Davis, Davis, CA) or pristane-
induced ascites of the 13.4 anti-TNP IgM hybridoma (provided
by J. Fleishman, Washington University, St. Louis, MO) were af-
finity purified on a TNP-BSA sepharose column followed by fast
protein liquid chromatography gel filtration with resulting 
 
 
 
98%
IgM purity by SDS-PAGE, or purified by immune affinity chro-
matography with an anti–mouse 
 
  
 
chain column (Sigma-
Aldrich). Control mouse myeloma IgM was obtained from Cal-
biochem-Novabiochem.
 
Statistics.
 
The paired two-tailed Student’s 
 
t
 
 test with P 
 
 
 
0.05 was taken as the level of significance.
 
Results
 
B Cells Are Required for CS Responses.
 
Current views of
the mechanisms responsible for CS exclude the participa-
tion of B cells. However, we found that CS responses fail
in gene-targeted JH
 
 
 
/
 
  
 
mice (Fig. 1), in which the disrup-
tion in IgH rearrangement specifically results in the ab-
sence of B cells (11). These mice are congenic to control
H-2
 
d 
 
CB.17 and BALB/c mice that have high CS respon-
siveness to PCl (TNP-Cl). In contrast, we previously
showed that CS to PCl also fails in the absence of B cells
in H-2
 
b 
 
 
 
MT mice (6), which also have a block in B cell
development but are low CS responders to PCl. Thus,
these studies with H-2
 
d 
 
CB.17 background JH
 
 
 
/
 
  
 
mice
(Fig. 1) confirm and extend prior findings by showing that
CS responses fail in the absence of B cells from two differ-
ent genetic lesions, rather than MHC-regulated respon-
siveness accounting for CS failure in B cell–deficient gene-
targeted mice.
Thus, when CB.17 JH
 
 
 
/
 
  
 
mice are immunized and chal-
lenged with PCl they show virtually no CS ear swelling ef-
fector response at 24 h (Fig. 1 a, left, solid bar) and have
greatly diminished local IFN-
 
  
 
production as a measure of
local CS effector T cell activation likely on APCs (Fig. 1 a,
right, solid bar). In contrast, when CB.17 wild-type con-
trol mice are sensitized and challenged with PCl they show
typical strong 24-h ear swelling (Fig. 1 a, left, open bar) and
local IFN-
 
  
 
production at 24 h (Fig. 1 a, right, open bar).
Thus, the recruitment of CS effector inflammatory T cells
and the subsequent activation for IFN-
 
  
 
production is
markedly impaired in B cell–deficient mice. Hence, B cells
are required to enable CS responses. 
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As in JH
 
 
 
/
 
  
 
mice, CS responses fail in CBA/N-
 
xid
 
 mice
(Fig. 1 b) that have a partial B cell deficiency that includes
all of the B-1 cells and a major subset of B-2 cells. Impor-
tantly, for these studies, the 
 
xid
 
 defect results in a virtually
complete absence of B-1 cells in mature animals and conse-
quently in very low serum IgM and minimal IgM responses
(12), enabling us to test whether B-1 cell–derived IgM is
involved in the elicitation of CS.
Using the standard CS protocol as outlined above, wild-
type CBA/J mice elicit an early 2-h ear swelling compo-
nent that we previously described as required for the subse-
quent elicitation of the classical 24-h component of CS
(15), which is accompanied by local elaboration of IFN-
 
 
 
assayed in ear extracts (6, 8). Thus, Fig. 1 b, line 2, shows
the 2-h and subsequent 24-h CS ear swelling in wild-type
CBA/J (left and middle), and in the right panel the accom-
panying 24-h ear extract IFN-
 
  
 
responses are shown. In
contrast, identical CS priming and challenge does not elicit
CS in 
 
xid
 
 mice. Notably, both the elicited 2- and 24-h CS
ear swelling responses are significantly lower in 4-d im-
mune 
 
xid
 
 mice than in similarly immunized and challenged
wild-type CBA/J mice (Fig. 1 b, left and middle, line 4 vs.
2). In addition, local production of IFN-  at 24 h is de-
creased significantly in xid animals (Fig. 1 b, right, line 4 vs.
2). Thus, the elicitation of CS fails in partially B cell–defi-
cient xid mice as in totally B cell–deficient JH /  (Fig. 1 a)
and  MT gene-targeted animals (6).
The xid Defect Prevents CS Initiation but Does Not Impair
Priming of CS Effector T Cells. Despite failure to elicit CS
in xid mice, in vitro studies show that LNCs from PCl-sen-
sitized xid mice respond to TNP-conjugated APCs (14) by
producing strong IFN-   responses comparable to those
stimulated in LNCs from sensitized control wild-type
CBA/J mice (Fig. 1 c). In addition, Ag-specific stimulation
of T cell proliferation with LNCs from xid mice is compa-
rable to control mice (unpublished data).
In vivo cell transfer studies similarly show that PCl prim-
ing induces normal CS effector activity in xid mice. These
experiments take advantage of the substantially greater ra-
pidity with which animals can be primed to produce the
2-h ear swelling response to secondary Ag challenge, which
is B cell–dependent compared with the production of the
full 2- plus 24-h CS response, which additionally depends
on the subsequent generation of sensitized effector T cells.
Thus, as previously shown, 1-d immune mice respond to
secondary challenge with hapten ear painting by producing
a strong 2-h ear swelling. However, the full 2- and 24-h
CS response does not follow because CS effector T cells
take 4 d to become fully sensitized after priming and are
not yet functional at day 1 (Fig. 2, line 1; reference 15).
Because transferring only the isolated T cells from 4-d PCl
immune donors into recipients primed 1 d previously with
PCl can reconstitute the full CS response (16), the 1-d im-
mune recipients enable testing the primed donors in the
presence of generated functional CS effector T cells.
Results with this assay show that CS effector T cells are
primed normally in the xid animals. Thus, when T cells
from 4-d PCl immune xid mice are transferred to 1-d PCl
immune wild-type CBA/J recipients, the xid T cells that
show little response in the donors (Fig. 1 b, line 4) produce
a strong 24-h CS effector T cell response in the 1-d im-
mune recipients (Fig. 2, right, line 2). In fact, this response
is similar to that mounted by similarly immunized wild-
type CBA/J controls (Fig. 1 b, middle, line 2). Therefore,
immunizing xid mice with PCl induces fully functional CS
effector T cells whose activity is not expressed in the xid
Figure 1. (a and b) Impaired elicitation of CS and accompanying local
generation of IFN-  in B cell–deficient JH /  and B-1 cell–deficient xid
mice, despite adequate generation of Th1 effector T cells. (a) 24-h macro-
scopic ear swelling (left) and 24-h ear extract IFN-  levels (right) were
compared in pan-B cell–deficient JH /  mice and normal CB.17 back-
ground controls. The pair of bars in each panel shows 4-d PCl contact-
sensitized wild-type controls (left, open bars) compared with similarly PCl-
sensitized JH /  CB.17 mice (right, solid bars). Background responses to
ear challenge in nonimmune controls of each strain were subtracted (n   6
mice per group). (b) Ear swelling responses elicited at 2 h and later at 24 h
in sensitized CBA/J (line 2) and B-1 cell–deficient CBA/N-xid male mice
(line 4; left and middle) ear challenged with PCl 4 d later. The right shows
the amount of IFN-  in 24-h ear extracts (n   6 mice per group). (c) In-
tact generation of Ag-specific IFN- –producing T cells in PCl-sensitized B
cell–deficient  xid mice. Bulk LNCs were prepared from PCl-sensitized
CBA/J and xid mice. After harvest on day 4, cells containing equal numbers
of T cells from each source were plated at 4   105 cells per well. The sensi-
tized cells were stimulated in vitro with various numbers of indicated hap-
ten-conjugated TNP-conjugated spleen cells as APCs, and 48 h later IFN- 
production in supernatants was measured by ELISA (n   6 per group).1281 Tsuji et al.
environment. However, T cell activity is readily demon-
strable after transfer to 1-d immune wild-type recipients
capable of mounting a B cell–dependent 2-h ear swelling
response, which initiates the elicitation of a full 24-h CS
response due to the immune xid CS effector T cells. In
contrast, mice immunized 1 d previously with another Ag
OX to control for nonspecific immunization effects, could
not initiate for PCl immune xid CS effector T cells with
PCl challenge (Fig. 2, line 3).
Thus, contrary to predictions based on current thinking,
two distinct mechanisms cooperate to act in sequence to
produce the classical 24-h CS response: one is required to
initiate CS and is missing in xid mice, whereas the other,
which induces the CS effector T cells, is fully functional but
not expressed because the T cells that mediate CS cannot be
recruited locally in the absence of the CS-initiating process.
Antigen Specificity Differences Confirm the Distinction between
CS Initiation and CS Effector Mechanisms. In typical CS
studies, successful responses to skin challenge are elicited by
using the same Ag for immunization and challenge, and the
specificity of the response is demonstrated by failure to re-
spond to challenge with a different hapten Ag. Thus, in the
cell transfer studies described above, responses were suc-
cessful when the same Ag was used to prime the 1-d im-
mune CBA/J recipient and the 4-d immune CS effector T
cell xid donor and when recipients were challenged after
the cell transfer with this Ag (Fig. 2, line 2). In addition, re-
sponses failed appropriately when different Ag were used
for priming or challenge (Fig. 2, lines 3 and 4). However,
the studies presented below show that fully successful re-
sponses to challenge in transfer recipients can be obtained
even when different Ag are used to immunize the effector
T cell donor and the CS-initiating host, provided that the
recipients are simultaneously challenged with a mixture of
both immunizing antigens.
For these “dual-antigen” experiments, we transferred
cells from 4-d PCl-immunized xid mice that have CS ef-
fector T cells responsive to PCl into 1-d OX-immunized
CBA/J mice (a different Ag), which, because they are 1-d
immune, did not yet have effector T cells capable of
mounting a 24-h CS effector response to the OX Ag.
Then, we challenged groups of such combined recipients
with each Ag separately (Fig. 2, lines 3 and 4) and another
group with both Ag together (Fig. 2, line 5). The results
show that OX elicits only the 2-h response in the 1-d OX
immune mice (Fig. 2, line 4) and 4-d PCl immune xid
hardly elicit any response (Fig. 2, line 3). Thus, here both
the 2- and the 24-h responses fail. However, in contrast, si-
multaneous challenge with both PCl and OX elicits the full
2- plus 24-h CS response (Fig. 2, line 5).
These findings demonstrate that successful elicitation of a
2-h CS initiation response, regardless of the Ag specificity
of this response, is sufficient to support the 24-h response
mediated by transferred CS effector T cells as long as the
challenge also includes the Ag recognized by the late-acting
effector T cells. The distinctive Ag specificities of the sepa-
rate early and late components of CS responses show that
separate mechanisms cooperate, acting in sequence to me-
diate the early initiation and the late effector phases of CS.
CS Responses Are Initiated by IgM Antibodies that React
with the Challenge Ag. The specificity and timing differ-
ences between the CS initiation and CS effector T cell
mechanisms, coupled with the failure of CS initiation in B
cell–deficient mice and our prior evidence indicating that
local complement activation and subsequent Ag-specific
C5a release are involved in CS initiation (5, 6, 8), suggest
that Ag–antibody complexes might be central to CS initi-
ation. This hypothesis is confirmed by studies in this sec-
tion, which show that intravenous injection of mono-
clonal IgM antibodies reactive with the challenge Ag
restores the initiation of CS effector T cell responses in
immunized xid mice.
We primed xid mice with PCl to induce CS effector T
cells that are ready to respond 4 d after priming but have
absent CS initiation (Figs. 1 b and 2). On day 3, we in-
jected purified IgM mAb from either of two anti-TNP
IgM hybridomas (32.17 and 13.4), each reactive with the
hapten self-products generated by PCl skin painting. On
day 4, we then challenged the mice with PCl (TNP-Cl).
Injection of 100  g of these mAbs enabled immunized
xid mice to elicit strong 24-h CS ear swelling responses
(Fig. 3 a, line 5 and b, line 4). In fact, injection of only 20
 g anti-TNP IgM was sufficient (Fig. 3 b, line 3). In con-
trast, no significant 24-h CS responses were detectable
when a similarly purified mouse myeloma IgM that does
not react with the challenge Ag was injected (Fig. 3 a, line
6), indicating that the initiation of the CS response requires
antibody specific for the challenge Ag.
Taken together, these findings demonstrate that CS effec-
tor T cells develop normally in xid mice and directly show
that the CS failure in these mice is due to a B cell defect that
interferes with their ability to produce IgM antibody. These
findings displace the current paradigm that states T cells
Figure 2. Ag-specific CS reconstitution by transfer of 4-d PCl immune
cells from xid donors into 1-d PCl immune CBA/J recipients. 4-d immune
xid donors of cells for transfer were primed with contact sensitizers and
1-d PCl or OX immune wild-type CBA/J recipient mice were challenged
with each Ag alone or with a mixture of PCl and OX. The xid PCl
immune cells were transferred intravenously (see Materials and Methods;
n   4 mice per group). ***, P   0.001 versus line 3. At 24 h, lines 3 and
4 were not significantly greater than line 1. P   0.01, lines 4 and 5 versus
line 3 at 2 h.1282 B-1 Cell IgM Antibodies Initiate Contact Sensitivity
alone mediate CS by showing that IgM antibodies are nec-
essary and sufficient to initiate CS effector responses for the
recruitment of the primed CS effector T cells.
Rapid IgM Antibody Responses After Immunization Act to
Initiate CS. Because we showed that CS responses are
initiated in 1-d primed animals, IgM antibodies to the
priming Ag should therefore be detectable in the 1-d im-
mune mice and should be capable of initiating CS. Accord-
ingly, the injection of serum harvested from 1-d PCl im-
munized wild-type mice is highly effective in enabling the
elicitation of both the 2- and 24-h CS response in PCl-
challenged 4-d PCl immune xid mice (Fig. 3 c, line 2). Im-
portantly, serum from nonimmune CBA/J mice is inactive
(Fig. 3 c, line 1), whereas serum from 1-d immunized ani-
mals is highly effective (Fig. 3, line 2). In addition, passage
of this latter immune serum through an anti-IgM column
removes activity, suggesting that IgM antibodies in the 1-d
immune serum are responsible for initiating CS. Thus, the
2-h activity produced by 1-d PCl immune sera in xid re-
cipients is 9.9   0.4 mm   10 2   SE compared with ear
swelling activity transferred by normal sera of 1.8   0.4.
Importantly, passage through an anti-IgM column reduced
the 1-d immune sera activity to 2.6 mm   10 2   0.7
(P   0.05) and transfer of the base eluate from this column
restored the response to 10.3   1.7. Therefore, we con-
clude that the production of CS-initiating IgM antibodies
is stimulated by skin painting immunization and surpris-
ingly begins within 1 d of immunization.
Ag specificity studies confirm and extend this conclu-
sion. Serum from 1-d OX immune animals is inactive in
PCl-immunized  xid mice that are challenged with PCl
(Fig. 3 c, line 3). However, injection of this anti-OX 1-d
immune serum into similar 4-d PCl-sensitized xid mice and
subsequent challenge with a mixture of PCl and OX results
in 2-h ear swelling that is CS-initiating, thus allowing the
elicitation of a full 24-h CS effector T cell response (Fig. 3
c, line 4). These findings confirm within the system the key
role that early Ag-specific antibodies play in initiating CS.
In addition, they reveal the mechanism underlying the
specificity distinction between early CS initiation and late
CS effector responses by showing that CS initiation is me-
diated by antibody, whereas CS effector responses are me-
diated by sensitized T cells.
1-d Immune B-1 Cells Produce CS-initiating Activity. Al-
though B-1 cells have been shown to produce IgM anti-
bodies in response to a variety of immunization protocols,
current thinking often relegates them either to a nonre-
sponsive role as producers of natural or unstimulated con-
stitutive antibodies, or to a minimal role as producers of
germ line–encoded antibody responses to a very limited set
of Ag. However, as we show in this section, B-1 cells re-
spond to CS immunization by rapidly producing CS-initi-
ating activity likely due to IgM antibodies.
We transferred 106 FACS®-sorted peritoneal B-1 cells
(98% pure CD5  B220 ) from nonimmune CBA mice
intraperitoneally into unimmunized CBA/N-xid mice,
primed the recipients by skin painting with PCl the next
day, and then skin challenged them with PCl 4 d later. CS
Figure 3. Antigen-specific monoclonal IgM or specific 1-d immune
sera reconstitute CS in sensitized xid mice. (a and b) Ag-specific anti-
TNP IgM reconstitutes 24-h CS ear swelling in immunized xid mice.
Normal CBA/J wild-type and B-1 cell–deficient xid mice were contact
sensitized on day 0 and ear challenged with PCl on day 4 to elicit CS (a,
line 2 vs. 1 and line 4 vs. 5). Results are shown for two purified mono-
clonal anti-TNP IgM antibodies, 32.17 IgM (a) and 13.4 IgM (b) in-
jected intravenously (n   6 mice per group). 100  g 32.17 IgM versus
100  g nonspecific IgM were injected intravenously 1 d before Ag
challenge on the ears with 0.4% TNP-Cl of 4-d PCl immune xid mice
(a). Either 20 or 100  g 13.4 IgM (lines 3 and 4) were injected intrave-
nously 1 d before Ag challenge into xid recipients that were immunized 3
days previously (b). (c) Antigen-specific reconstitution of 24-h CS in
immunized CBA/N-xid with 1-d immune sera. Transfer of 1-d PCl
immune CBA/J sera (0.7 ml) mediated 2-h ear swelling and reconstituted
24-h CS in 4-d PCl immune xid mice (line 2), whereas normal sera was
inactive (line 1). 1-d OX immune sera did not have this activity (line 3).
However, the combination of active 4-d PCl CS of xid recipients and the
transfer of 1-d OX immune sera resulted in 2-h ear swelling and reconsti-
tuted 24-h CS when the PCl immune xid mice were challenged with a
mixture of PCl and OX (line 4) compared with double challenged con-
trols (line 5; n   4 mice per group).1283 Tsuji et al.
responsiveness measured at 2 and 24 h is restored in usually
unreactive xid, although incompletely (Fig. 4 a, group E vs.
C). In addition, there is fully restored 24-h chemotactic ac-
tivity assayed in CS ear extracts (Fig. 4 b, right, group E vs.
D and C), which we previously showed depends on che-
mokines like IP-10 that are induced locally by IFN-  (8).
Similarly, 2-h chemotactic activity, which we previously
showed to be dependent on local generation of C5 (8) and
thus is an indicator of CS initiation, is also restored strongly
(Fig. 4 b, left, group E vs. B). Thus, by all of these macro-
scopic and biochemical measures, the transfer of FACS®-
purified B-1 cells isolated from unimmunized wild-type
mice into xid before immunization, largely restores CS re-
sponsiveness after priming and challenge.
The ability to initiate CS in response to secondary Ag
challenge is also restored by transfers of 1-d immune lym-
phoid cells (LN plus spleen) before challenge of primed B
cell–deficient recipient mice. First, the transfer of lymphoid
cells from 1-d PCl or OX immune CBA/J donors to un-
immunized xid mice enables 2-h CS responses to the cog-
nate priming Ag PCl or OX, but without 24-h responses
due to T cells that are not generated until day 4 (Fig. 5 a,
left, groups A and B). Second, the transfer of these 1-d im-
mune lymphoid cells into 4-d immune xid mice mediates a
2-h CS initiation response that enables elicitation of the
24-h CS effector response to the homologous TNP Ag
(Fig. 5 a, right, group C vs. E and group G vs. H). How-
ever, transfers of wild-type lymphoid cells that are 1-d im-
mune to another Ag (OX) into xid mice that are immune
to a different Ag (PCl) and challenge with the cognate Ag
PCl, fails to restore 24-h CS (Fig. 5 a, right, groups D and
E). Thus, transferring B cell–containing lymphoid popula-
tions from 1-d immune donors is equivalent to injecting
IgM antibodies from these donors in that both provide
strong Ag-specific support for CS initiation.
FACS® sorting studies show that the responding B cells
within the lymphoid populations from 1-d immunized do-
nors are small numbers of B-1 cells. To isolate these cells,
we used the CD19 and CD5 markers, which are present on
B-1 (B-1a) cells (12) and the CD43 marker, which has
been shown to be present on most but not all CD19 
CD5  B-1 cells (13). Consistent with the known distribu-
tion of these markers,  90% of the cells in the small frac-
tion of CD19  CD5  B-1 cells ( 1–2% of all cells) de-
tected in the LNs and spleen were CD43 . Both of the
CD43  (300   103) and the CD43  (160   103) B-1 sub-
populations enabled 2-h CS-initiating responses to Ag
challenge when transferred to xid mice that were immu-
nized 4 d previously with the Ag used for challenge (Fig. 5
b, left, groups E and F). In addition, both of these B-1 sub-
populations mediate the initiation of elicitation of strong
24-h CS responses (Fig. 5 b, right, groups E and F).
Dose response transfer of the 1-d immune CD19 
CD5  CD43  lymphoid cells showed that 100   103, and
as few as 30   103 FACS®-sorted CD43  B-1 cells, trans-
ferred to 4-d PCl immune xid mice the ability to elicit
strong 24-h responses (Fig. 5 b, right, group H). In con-
trast, the transferred 2-h reactivity decreased progressively
with the number of transferred B-1 cells until 2-h reactiv-
ity was insignificant at 30   103 (Fig. 5 b, left, groups F–H).
In contrast, the mediation of 24-h CS was maintained,
demonstrating that optimal macroscopic 24-h CS effector
T cell responses do not require optimal macroscopic CS
initiation responses, which are likely based on microvascu-
lar activation. Thus, macroscopic suboptimal 2-h responses
due to B-1 cell IgM antibody can support effective 24-h T
cell responses.
We tested whether these results were special to xid mice,
as we considered that residual B cells in xid mice might
contribute to our findings. Thus, we used pan B cell–defi-
cient JH /  mice in similar experiments. The transfer of
mixed lymphoid cells, or 100   103 FACS®-purified B-1
cells (CD19 CD5  subdivided into CD43  or CD43 ),
into immunized JH /  recipients again showed that B-1
cells in the LN and spleen from 1-d immune BALB/c H-2d
donors are sufficient to restore both the 2- and 24-h CS re-
Figure 4. Normal B-1 cell reconstitution before immunization restores
2- and 24-h CS in CBA/N-xid and restores elaborated 2- and 24-h che-
motactic activity. (a) FACS®-sorted peritoneal B-1 cells (98% CD5 
B220 ) obtained from intact wild-type CBA/J mice were transferred in-
traperitoneally to xid the day before PCl sensitization and 2- and 24-h CS
responses were elicited on day 4 (n   6 mice per group). ***, P   0.001
group B versus A, and group E versus F at 2 and 24 h; *, P   0.01 versus
group E versus F. (b) Data show chemotactic activity for migrated
J774A.1 macrophages in the extracts of ears at 2 and 24 h in the indicated
mouse strains that also were shown in a, and were immunized and
challenged as indicated (n   6 mice per group). ***, P   0.001 group B
versus A, and group E versus F; **, P   0.02 versus group B versus A, and
group E versus F at 24 h.1284 B-1 Cell IgM Antibodies Initiate Contact Sensitivity
sponses in these fully B cell–deficient animals (Fig. 5 c,
groups D–F). Thus, B-1 cells in 1-d immunized wild-type
mice are necessary and sufficient for mediating Ag-specific
initiation for CS effector T cell responses in either xid or
JH /  mice. Because monoclonal IgM antibody or anti-
body produced by 1-d immunized animals is also necessary
and sufficient to enable CS initiation, we conclude that
transferred B-1 cells produce these IgM antibodies in the B
cell–deficient recipients and thereby enable the CS initia-
tion process.
Interestingly, transferred B-1 cells fully reconstituted the
24-h CS response in JH /  mice (Fig. 5 c, groups D–F),
whereas in xid mice they only partially restore 24-h macro-
scopic CS responses (Fig. 4 a). This might be due to other
defects specific to xid mice that could contribute to elicita-
tion of CS responses, such as in mast cells (17) and mac-
rophages (18). However, the difference may also be due to
difficulties in effectively transferring B-1 cells into an envi-
ronment that already contains B cells because the long-
term establishment of B-1 cells in unirradiated xid mice is
difficult to achieve (unpublished data).
Later in the Immune Response, B-2 Cells Provide Support for
CS Initiation. Although FACS®-purified B-1 cells har-
vested from 1-d immune donors readily enable CS initia-
tion in immunized B cell–deficient mice, B-2 cells har-
vested at this early time are unable to do so. However,
several days later, at a time when B-2 cells typically begin
differentiating into cells producing antibodies to the immu-
nizing Ag, B-2 cells also become capable of restoring CS
initiation in B cell–deficient recipients.
In these studies, we transferred FACS®-purified B-1 and
B-2 cells obtained from BALB/c mice at various days after
PCl immunization into 4-d PCl-immune JH /   mice,
which are congenic to BALB/c and can therefore accept
BALB/c cell transfers (Fig. 6). As in the xid transfers, B-1
cells (CD19  CD5 ) from 1-d immune donors readily re-
constitute 24-h CS (Fig. 6, right, group C) to thus recon-
stitute both the 2- or 24-h CS response (Fig. 6, group C).
In contrast, 4 d after immunization, both the B-1 and
B-2 cells from the immunized donors could initiate CS
(Fig. 6, groups E and F), but by 8 d after immunization the
activity had shifted entirely into the B-2 population (Fig. 6,
groups G and H). Thus, B-2 cells, like B-1 cells, are able to
mediate the initiation of CS. However, they require a
longer time after immunization for this activity to develop
and as a population retain this activity for a longer time
once it develops.
Because we concluded that CS initiation by B-1 cells is
due to the production of IgM antibodies to the challenge
Figure 5. 1–d immune B-1 cells reconstitute CS in 4-d immune xid or
JH    mice. (a) 1-d PCl or OX immune cells transfer 2 but not 24 h reac-
tivity (groups A and B). Reconstitution of 2- and 24-h CS in 4-d immune
CBA/N-xid mice by transfer of these 1-d wild-type immune cells. Per Ag
specificity, the 1-d PCl immune CBA/J wild-type cells were transferred
to the indicated 4-d OX immune xid recipient mice and challenged as in-
dicated either with OX (group F) or 1-d OX immune cells were trans-
ferred to 4-d PCl immune xid recipients challenged with PCl (group D;
n   4 mice per group). P   0.001, group C versus A, D, and E at 24 h.
P   0.001, group G versus F and H at 2 and 24 h. (b) Reconstitution of
CS by transfer of 1-d PCl immune B-1 cells to 4-d PCl immune B cell–
deficient recipients. 1-d immune CBA/J mixed cells (group C) or FACS®-
sorted B-1 cells (groups E–H) transferred to 4-d immune xid mice medi-
ates CS. For dose response, 3   104   3   106 B-1 cells (CD19  CD5 
CD43  or CD19  CD5  CD43 ) that were FACS®-sorted 1-d immune
spleen and LNCs were transferred to 4-d immune xid mice. The recipi-
ents were tested for CS elicitation, showing reconstitution of CS by B-1
cells at all doses tested to 3   104 cells (n   4 mice per group). ***, P  
0.001; **, P   0.01; *, P   0.05 versus group B. (c) Transfer of 1-d immune
FACS®-sorted CD43  and CD43  BALB/c B-1 cells (CD19  CD5 ) to
4-d PCl immune JH    recipient mice reconstitutes CS (n   4 mice per
group). P   0.001, groups D–F versus C at 24 h.1285 Tsuji et al.
Ag, these findings indicate that B-1 cells develop the ability
to produce the necessary antibodies within 1 d of immuni-
zation and lose that ability  1 wk later. In contrast, B-2
cells only develop the ability to produce the necessary anti-
bodies 4 d after immunization, but they seem to retain that
ability longer than B-1 cells. Thus, with respect to the clas-
sical murine CS response, which is elicited by Ag priming
on day 0 and challenging on day 4, most or perhaps all of
the antibody that participates in CS initiation needed for
elicitation of the CS effector T cell response is produced by
B-1 cells.
Discussion
Synopsis. These studies make four related observations
that together demonstrate for the first time that B cells, via
the antibodies they produce, are responsible for initiating
the elicitation of a classical T cell–mediated in vivo re-
sponse. CS as an example of DTH has universally been
considered to be a purely T cell response that does not re-
quire the participation of B cells. However, here we show
that (a) both the 2-h CS initiation phase and the subse-
quent 24-h effector T cell phase of the elicited CS response
fails in B cell–deficient mice primed via standard contact
sensitization with the Ag then used for secondary stimula-
tion via skin challenge, (b) both responses are restored in
these mice by the introduction of monoclonal IgM anti-
bodies specific for the challenge Ag, and (c) the 2- and 24-h
CS responses are similarly restored by the introduction of
either B-1 cells or serum from wild-type mice primed just
1 d previously with the challenge Ag. Thus, we conclude
that IgM antibodies initiate the postulated cascade of events
that culminates in the successful elicitation of CS effector T
cell responses and that B-1 cells responding rapidly to the
primary immunization produce the IgM antibodies that
initiate the elicitation of CS.
Relation to Prior Findings in CS. These novel findings,
summarized in Fig. 7, were foreshadowed by our previous
studies findings. Those studies showed in a model system
that IgE or IgG1 antibodies reactive with the challenge Ag
were required to initiate 24-h CS responses mediated by
isolated CS effector T cells (19). Because both of these iso-
types are known to bind to Fc receptors on mast cells, we
interpret findings in this system as indicating that local Ag
challenge stimulated mast cells via the bound antibodies to
release vasoactive mediators that initiated the recruitment
of the CS effector T cells (19).
More recently, in studies that led to the work presented
here, we showed that secondary Ag challenge in 4-d con-
tact-sensitized mice results in the Ag-specific local, early
(1–2 h) generation of complement-derived C5a (8). Be-
cause C5a binds to C5a receptors (8) and most likely acts
indirectly in CS to trigger both mast cells (20) and platelets
(21), we suggested that C5a therefore leads to local endo-
thelial activation (22), which results in the recruitment of
the CS effector T cells responsible for eliciting the full 24-h
CS response. These earlier findings imply the participation
of complement-binding Ag–antibody complexes in CS ini-
tiation because such complexes are the most likely mecha-
nism for generating C5a. In contrast to the IgM-facilitated
and C5a-mediated CS initiation described here, Arthus hy-
persensitivity reactions, although also dependent on com-
plement, are instead mediated by very large amounts of
high affinity hyperimmune IgG antibody. Alternatively,
IgG can also act in DTH via Langerhans cells to aid the in-
duction of immunization (23) rather than the elicitation of
responses. Finally, IgG1 can act via mast cell Fc receptors to
elicit late phase cutaneous basophil DTH (24, 25).
These studies test and confirm the hypothesis that IgM–
Ag complexes generate C5a that initiates CS for T cells by
showing directly that IgM antibodies specific for the chal-
lenge Ag are required to elicit CS. Neither the challenge
Ag alone nor the antibody alone is sufficient for this pur-
pose. Both must be present. Thus, taking our earlier find-
ings into account, we propose that the binding of IgM an-
tibodies to the challenge Ag at the challenge site results in
the formation of local, complement-activating Ag–anti-
body complexes that generate C5a to trigger the rest of the
CS initiation pathway. For these studies we focused on the
transfer of IgM just before the elicitation of CS, rather than
Figure 6. Comparing the ability of wild-type immune
B-1 versus B-2 cells harvested various days after PCl sensi-
tization to reconstitute CS in JH /  mice. 1-, 4-, or 8-d
PCl immune FACS®-sorted B-1 cells (CD19  CD5 ) or
1-, 4-, or 8-d immune FACS®-sorted B-2 cells (CD19 
CD5 ) all at 150   103 cells per recipient from PCl-immu-
nized BALB/c donors were transferred to indicated groups
of 4-d PCl immune JH /  recipients, which were chal-
lenged with PCl Ag and elicited 2- and 24-h measured CS
ear swelling responses (n   4 mice per group).1286 B-1 Cell IgM Antibodies Initiate Contact Sensitivity
before immunization to rule out any possible role of trans-
ferred IgM in antigen presentation for sensitization. How-
ever, the transfer of IgM-producing B-1 cells (Fig. 4), or
even the transfer of purified hybridoma anti-TNP IgM be-
fore sensitization (unpublished data), also reconstituted CS
in immunized xid mice, presumably via IgM availability to
complex with challenge Ag and generate local C5a.
Others have suggested that local Ag challenge used for
the elicitation of CS can lead to early activation of kerati-
nocytes, which then produce factors that are responsible for
initiating T cell recruitment (26). Our data argue against
this formulation because keratinocyte development and
function is not likely to be impaired in B cell–deficient
mice and because the B-1 cell–derived IgM antibody that
we show reconstitutes CS has no known activating effects
on keratinocytes.
One wonders how the key role that IgM antibodies play
in initiating CS could have been missed in over 50 yr of
study. Part of the explanation may lie in the general accep-
tance of the “solely due to T cells” paradigm, which im-
peded investigations that might have tested whether B cells
or antibodies also could participate. We also tended to go
along with this view, but only began to examine B cell and
antibody participation in the elicitation of CS responses
when we were led to this idea by the surprising finding that
complement C5 (6, 7) and Ag-specific local generation of
C5a (8) were involved in CS initiation. In addition, we
were unwilling to accept this new idea that CS is antibody
dependent until we had thoroughly explored potential lim-
itations in our data.
Proof that B-1 Cell IgM Plays a Crucial Role in CS Initia-
tion. For example, the demonstration here that the injec-
tion of monoclonal IgM antibody reactive with the chal-
lenge Ag restores CS initiation in B cell–deficient mice
should in principle be sufficient to solidly implicate anti-
bodies in this process. However, establishing that antibod-
ies play a role in CS initiation under normal conditions re-
quires the demonstration that primary immunization by
skin painting can stimulate antibody production rapidly
enough to be effective, because animals are typically chal-
lenged only 4 d after priming (1, 15). This very early pro-
duction of IgM seemed unlikely because IgM antibody
responses to cell-bound Ag such as those on sheep erythro-
cytes are seldom detectable until at least 4 d after immuni-
zation and IgM responses to soluble proteins arise even
later at 5–7 d after priming (27, 28). Nevertheless, as we
have shown, direct evaluation of antibody responses to skin
painting with a contact sensitizing hapten demonstrates that
this mode of immunization induces IgM antibody produc-
tion so rapidly that antibody levels sufficient to initiate CS
Figure 7. B-1 cell CS initiation
for the recruitment of CS effector T
cells. (1) Primary sensitization for the
future elicitation of CS responses by
painting reactive chemical hapten
Ag (e.g., PCl) on the skin of the
body. (2) Local secondary Ag chal-
lenge by painting the ears with a di-
lute solution of the sensitizing hap-
ten Ag PCl to elicit CS responses.
On day 1 after sensitization, Ag
challenge elicits 2-h ear swelling
without 24-h swelling (reference
16), due to the development of im-
mune B-1 cells producing IgM anti-
body in the absence of sensitized T
cells. (3) Local complement is acti-
vated (references 5 and 6) by im-
mune complexes of B-1 cell IgM
plus Ag to generate C5a (references
7 and 8). (4) Mast cells (reference
20) and platelets (reference 21) are
activated by C5a by stimulating C5a
receptors (reference 8) to release se-
rotonin (references 1 and 19) and
TNF-   (references 8 and 22) that
activate local endothelial cells (refer-
ence 22) to generate the 2-h CS-ini-
tiating response. Released TNF- 
induces endothelial expression of
ICAM-1 and VCAM-1 (reference 22) to facilitate local recruitment of the CS effector T cells (references 15 and 16) to produce inflamatory cytokines
like IFN-  (reference 6) that induce chemokines like IP-10 (reference 8). (5) This allows the recruitment of the CS effector T cells developed by day 4
at the site of challenge to mediate the classical 24-h ear swelling response. In addition, C5/C5a-independent CS-initiating pathways, e.g., challenge Ag
that binds to IgE antibody bound to Fc  receptors on mast cells (reference 19), can provide similar CS-initiating function at later times after immuniza-
tion. (6) CS initiation leads to the recruitment of circulating CS effector T cells that were sensitized at least 4 d previously to the same Ag presented by
the secondary challenge. Note that the Ag on the APCs recognized by the T cells need not be the same as that recognized by the IgM antibodies that ini-
tiate the elicitation of the response. Also, immune T cells transferred intravenously before challenge in recipients with a source of CS-initiating IgM an-
tibody can substitute for the native endogenous CS effector T cell population.1287 Tsuji et al.
are already present in the circulation 1 d after priming.
Thus, we conclude that skin painting immunization clearly
induces B cells to produce enough specific IgM antibody
for CS initiation 4 d after priming, when the effector T
cells are generated.
To identify the B cell subset responsible for this very
early production of antibody, we evaluated FACS®-sorted
B-1 and B-2 cell populations from wild-type immunized
donors for their ability to restore CS initiation in 4-d im-
mune B-1 (xid) and pan B cell–deficient (JH / ) recipi-
ents, which we show have generated sensitized CS effector
T cells but lack ability to produce antibodies needed to lo-
cally recruit these cells. We found that both B-1 and B-2
cells produce sufficient amounts of antibody to enable CS
initiation when transferred to these B cell–deficient recipi-
ents. Significantly, however, only the B-1 cells respond
rapidly enough to be active when taken from 1-d immu-
nized donors. In fact, as few as 30,000 FACS®-purified
B-1 cells from these 1-d immune donors is sufficient to re-
store CS initiation.
Relation to Prior Findings in B-1 Cells. Together, these
findings introduce a new role for immunized B-1 cells as
rapid producers of IgM antibodies that initiate CS and po-
tentially other T cell–dependent inflammatory responses.
This novel function for B-1 cells is surprising because B-1
cells are usually known as producers of natural IgM anti-
bodies and are commonly thought either to be unable to
respond to immunization or to respond only to T-inde-
pendent Ag. However, a closer examination of the litera-
ture shows that B-1 cells have been shown to produce anti-
bodies to the DNP/TNP hapten that is used here to induce
CS when the hapten is presented on an appropriate carrier
(28). In perhaps the best example of the potential breadth
of B-1 antibody responses, B-1 cells produce antibodies to
phosphorylcholine presented either in its natural T-inde-
pendent form as an Ag coat of pneumoccocal polysaccha-
ride or in a T-dependent form as a hapten linked to certain
carrier proteins such as keyhole limpet hemocyanin (28–
32). The rapidity of the B-1 response we noted also has
precedents with stimulation via nonspecific LPS (33–35)
and pneumococcal polysaccharide (36, 37).
Our identification of functional antibody-producing cells
in the spleen and LN rapidly after contact sensitization,
which likely reflects the migration of activated peritoneal
B-1 cells to these peripheral lymphoid sites, has parallels in
more recent work. Studies in Ig transgenic mice demon-
strate that some B-1 cells can migrate from the peritoneal
cavity to the lamina propria of the gastrointestinal tract
where they produce IgA antibodies (38, 39). Thus, there
are precedents to our demonstration that B-1 cells can rap-
idly produce IgM antibodies and can migrate to peripheral
lymphoid sites for antibody production.
It is not known how hapten-specific peritoneal B-1 cells
are rapidly stimulated to produce CS-initiating IgM anti-
body. However, we know that hapten–self-protein com-
plexes emanate from the skin site of contact sensitization
for distribution throughout the body via the circulation
(40). Thus, it is likely that Ag is distributed from the skin to
the peritoneal cavity where B-1 cells are found preferen-
tially (12). In fact, our results show that B-1 cells in the
peritoneal cavity are activated for CS initiation within
hours after immunization (unpublished data). We postulate
that IgM anti-TNP Ig receptors of higher affinity on these
B-1 cells are cross-linked by multivalent Ag dispersed from
the skin site of sensitization. This may stimulate Ag-specific
IgM production by activated B-1 cells migrating to the
lymphoid tissues, as shown for IgA-producing B-1 cells in
the GI tract (38, 39). In addition, we find that IL-4 is
needed as a costimulus for IgM production by the B-1 cells
and appears to be released rapidly after sensitization by
NKT cells (41, 42).
Thus, these findings introduce a new view of B-1 cell
responsiveness and of the previously unsuspected impor-
tance of these cells to in vivo T cell–mediated immune ef-
fector responses. As we have shown, the rapid antibody
response mounted by B-1 cells in contact-sensitized mice
constitutes the first and required step in what was previ-
ously considered to be an exclusively T cell immune re-
sponse. Without the antibody produced by B-1 cells to
initiate this required sequence, the traditional CS response
fails despite the development of CS effector T cells,
which, although present, cannot be recruited locally.
Thus, our findings are a surprising inversion of the classical
immunological paradigm in which T cells help B cells in
antibody responses, which still stands. However, our find-
ings insert antibody production by B-1 and sometimes by
other B cells as a necessary first step in the elicitation of a
classical in vivo effector T cell CS response, i.e., B cells
can help T cells.
Biologic Relevance of B-1 Cell IgM Mediation of CS Initia-
tion. From a clinical perspective, our findings may offer a
new pathway for triggering delayed and contact hypersen-
sitivity and related DTH reactions and therefore potentially
provide new routes for therapeutic intervention. B cells are
in fact already known to participate in a variety of T cell–
mediated disease models of mice including autoimmunity
in collagen arthritis (43), nonobese diabetes (44), lupus-like
lesions of lpr/lpr mice (45), encephalomyelitis (46), and
also in T cell protection against infections (47). However,
to date, the participation of B cells in these disease re-
sponses has largely been interpreted as due to their afferent
APC function needed to induce the sensitized T cells (48,
49). In contrast, our findings show that B-1 cell IgM can
mediate the required early steps in the efferent phase of CS
with no role in the induction of the CS effector T cells.
This suggests that antibodies may participate in the elicita-
tion of the efferent T cell responses in at least some of the
clinical conditions listed above, particularly in disease mod-
els like collagen arthritis and encephalomyelitis, where B
cells (46), antibodies (50, 51), complement (52, 53), and
mast cells (54–57) have all been implicated in mediation of
the efferent T cell responses.
Importantly, we have shown that the Ag recognized by
the antibodies capable of forming early phase complement-
activating complexes and leading to the recruitment of T
cells to the CS site, need not be of the same Ag specificity1288 B-1 Cell IgM Antibodies Initiate Contact Sensitivity
as the Ag recognized by the CS effector T cells that cause
late phase inflammation and possibly damage at the site. T
cells sensitized to a particular Ag can in fact be recruited by
complement-activating antibodies like IgM that recognize
and form complexes with any Ag that is locally concen-
trated or by antibodies of other isotypes like IgE that di-
rectly activate mast cells (19). If the Ag that the T cells rec-
ognize is also present at this site along with the Ag
recognized by the antibody, then diverse, available sensi-
tized T cells can be recruited and selected subsets can be ac-
tivated by their Ag expressed as peptides on local APCs.
This dual Ag effect can thus produce a classical CS response
regardless of whether the T cells recognize the same Ag as
the initiating antibodies. Therefore, antibodies to a variety
of locally present Ag (bacterial, viral, or allergens) could in
theory initiate CS, DTH, or other T cell responses in
which the effector T cells are activated by responding lo-
cally to another Ag that is expressed on the local APCs.
This dual Ag CS initiation mechanism, therefore, could
provide the basis for responses that contribute to the well-
known synergy between infections and allergy (58) or au-
toimmunity (59).
As a practical matter, the dissociation of the specificity of
the response trigger from the specificity of the response ef-
fector mechanism that acts in an obligate sequence, may
make the etiology of disease processes initially more diffi-
cult to discern. However, once this Ag duality of separate
and sequential antibody-mediated initiating and T cell–
dependent late effector phases is recognized, it may open
the way to unraveling cause and effect in complex immu-
nological disease situations and therefore offer new targets
and routes for therapeutic intervention.
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